id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
NRC-2022-0218-0195,NRC,NRC-2022-0218,"LTR-24-0219 Dana Smetherman, Chief Executive Officer, American College of Radiology, Letter re: SECY-24-0067 on Proposed Rule - Reporting Nuclear Medicine Injection Extravasation as Medical Events",Supporting & Related Material,,2025-02-11T00:00:00Z,2025,2,,,2025-05-21T06:20:58Z,,0,0,090000648694f2b4
NRC-2022-0218-0196,NRC,NRC-2022-0218,10-16-24 Letter from Simon Davies to NRC,Supporting & Related Material,,2025-02-11T00:00:00Z,2025,2,,,2025-05-21T06:20:57Z,,0,0,090000648694f2b5
NRC-2022-0218-0199,NRC,NRC-2022-0218,10-21-24 DG-8062 Public Comment From YSC,Supporting & Related Material,,2025-02-11T00:00:00Z,2025,2,,,2025-05-21T06:20:58Z,,0,0,090000648694f2b8
NRC-2022-0218-0197,NRC,NRC-2022-0218,"LTR-24-0227 Simon Davies, Executive Director, Teen Cancer America, Patients for Safer Nuclear Medicine Spokesperson, comments on Nuclear Regulatory Commission's Draft Regulatory Guide DG-8062 for radiopharmaceutical extravasation reporting",Supporting & Related Material,,2025-02-11T00:00:00Z,2025,2,,,2025-05-21T06:20:58Z,,0,0,090000648694f2b6
NRC-2022-0218-0198,NRC,NRC-2022-0218,Venus Gines Commenting on Draft Regulatory Guide,Supporting & Related Material,,2025-02-11T00:00:00Z,2025,2,,,2025-05-21T06:20:58Z,,0,0,090000648694f2b7